Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation due to ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $27.00.

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

Pfizer delayed the announcement of its COVID-19 vaccine until after the 2020 election when it thought Donald Trump was ...

One of the most promising aspects of AI and its integration into the pharmaceutical industry is the technology’s potential to ...

Formation Bio, an AI-driven pharmaceutical company revolutionizing drug development, today announced that Mikael Dolsten, MD, PhD, former Chief Scientific Officer and President, Pfizer Research & ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...

President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.